Dashboard Market News Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Fate Therapeutics Inc banner

Fate Therapeutics Inc
NASDAQ:FATE

Watchlist Manager
Fate Therapeutics Inc Logo
Fate Therapeutics Inc
NASDAQ:FATE
Watchlist
Price: 2.33 USD -4.51% Market Closed
Market Cap: $271.6m
Write Note Create Alert Ask AI

Wall St Price Targets

FATE Price Targets Summary
Fate Therapeutics Inc

Wall Street analysts forecast FATE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for FATE is 5.61 USD with a low forecast of 2.22 USD and a high forecast of 8.4 USD.

FATE Lowest Forecast
Wall Street Target
$2.22
-5% Downside
FATE Average Forecast
Wall Street Target
$5.61
141% Upside
FATE Highest Forecast
Wall Street Target
$8.4
261% Upside
Lowest Forecast
Price Target
2.22 USD
5% Downside
Average Forecast
Price Target
5.61 USD
141% Upside
Highest Forecast
Price Target
8.4 USD
261% Upside
Fate Therapeutics Inc Competitors:
Price Targets

Revenue
Forecast

7% / Year
Past Growth
70% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat
7% / Year
Past Growth
70% / Year
Estimated Growth
Estimates Accuracy
0%
Average Beat

Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 8 years is 70%.

What are analyst estimates?

Gross Profit
Forecast

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss
N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average Beat/Miss

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Pre-Tax Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-3%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-2%
Average Miss

What are analyst estimates?

Continue FATE Research

Summary
FATE intrinsic value, competitors valuation, and company profile.
DCF Valuation
FATE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
FATE stock valuation using valuation multiples.
Wall St Estimates
FATE price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
FATE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Fate Therapeutics Inc listings:
F • EUR
F6T
 SWB • EUR
F6T
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is FATE's stock price target?
Price Target
5.61 USD

According to Wall Street analysts, the average 1-year price target for FATE is 5.61 USD with a low forecast of 2.22 USD and a high forecast of 8.4 USD.

What is the Revenue forecast for Fate Therapeutics Inc?
Projected CAGR
70%

Over the last 13 years, the compound annual growth rate for Revenue has been 7%. The projected CAGR for the next 8 years is 70%.

Back to Top
ALPHA SPREAD
Follow us
Join 357,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.